ZVRA Stock Forecast & Price Target

Zevra Therapeutics Inc. has demonstrated robust market demand for its ultra-rare Niemann-Pick type C (NPC) therapy, MIPLYFFA, achieving sales of $10.1 million in Q4 2024, which significantly exceeded analyst estimates. The company has seen an increase in TRx enrollment forms from 90 to 109, indicating a growing patient base and strong interest in its offerings amid ongoing efforts to enhance disease awareness among healthcare providers. Looking ahead, Zevra's 2025 sales outlook appears promising, bolstered by continued patient acquisition, successful commercial strategies, and potential expansion into the European market, solidifying the company's position in the rare disease therapeutic landscape.

Zevra Therapeutics Inc. is facing significant financial challenges, including a substantial GAAP net loss of $20.4 million due to non-cash charges, alongside a deepening 4Q net loss of $35.7 million driven by high R&D and SG&A expenses. Furthermore, the company is experiencing slow product launches, with a lack of investor interest and risks related to payer coverage impacting sales conversions and demand, particularly for its drug Miplyffa in light of recent competitive approvals. Additionally, emerging safety and tolerability concerns, combined with the potential failure of pipeline programs, threaten to reduce future development options and limit overall growth prospects.